Sign Out
The patient should not use PMS-BORTEZOMIB if she is pregnant, unless clearly necessary.
Both men and women receiving PMS-BORTEZOMIB must use effective contraception during and for up to 3 months after treatment. If, despite these measures, pregnancy occurs, the patient must be advised to inform the doctor immediately.
The patient should not breast-feed while using PMS-BORTEZOMIB. She must be advised to discuss with the doctor when it is safe to restart breast-feeding after finishing the treatment.
Thalidomide causes birth defects and fetal death. When PMS-BORTEZOMIB is given in combination with thalidomide, the patient must be advised to follow the pregnancy prevention programme for thalidomide (see package leaflet for thalidomide).
Continue with Google